Study demonstrates excellent analytical accuracy, repeatability, and reproducibility of the assay NEW YORK , Aug. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD ) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
(Nasdaq: PAVM ), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard ® Esophageal DNA test for the diagnosis of esophageal precancer (Barrett's Esophagus or BE) and esophageal adenocarcinoma (EAC) on samples collected non-endoscopically using Lucid's EsoCheck ® Esophageal Cell Collection Device . The manuscript, entitled Analytical Validation of a DNA Methylation Biomarker Test for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma from Samples Collected Using EsoCheck ® , a Non-Endoscopic Esophageal Cell Collection Device , has been published in the peer-reviewed journal Diagnostics , and is currently available via open access online. "This analytical validation study strongly complements EsoGuard's extensive peer-reviewed, published clinical validity and clinical utility evidence base," said Suman Verma , M.
D. , PhD, Lucid's Chief Scientific Officer. "The results demonstrate very robust analytical performance of the EsoGuard assay performed in our CLIA-certified, CAP-accredited, NY State-approved commercial laboratory.
" The publication details comprehensive studies demonstrating excellent analytical performance of th.